Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
Pfizer (NYSE: PFE) completed its acquisition of Metsera on November 13, 2025, buying all outstanding Metsera shares for $65.60 per share in cash and an enterprise value of approximately $7.0 billion.
The deal includes a contingent value right (CVR) of up to $20.65 per share tied to three clinical and regulatory milestones. Metsera is now a Pfizer subsidiary and its common stock will cease trading on NASDAQ. Key assets transferred include MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog in Phase 1), an oral GLP-1 RA in Phase 1, and preclinical hormone therapeutics.
Pfizer expects the transaction to be dilutive through 2030 and will update financial outlook with 2026 guidance later this year.
Pfizer (NYSE: PFE) will webcast a discussion with Dave Denton, CFO, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.
Investors and the public can register and access the live webcast at www.pfizer.com/investors. A transcript and replay will be posted within 24 hours after the live event and will remain available for at least 90 days. Registration information is available beginning today on the investor website.
The webcast may include forward-looking statements; risk factors are available in Pfizer's Form 10-K for the year ended December 31, 2024 and subsequent SEC reports.
Pfizer (NYSE: PFE) reported Q3 2025 revenues of $16.7B and raised and narrowed full-year 2025 adjusted diluted EPS guidance to $3.00–$3.15 while reaffirming revenue guidance of $61.0–$64.0B. Q3 adjusted diluted EPS was $0.87 and reported diluted EPS was $0.62. The company delivered ~$7.2B anticipated net cost-savings target by end of 2027 trajectory and invested $7.2B in internal R&D in the first nine months. The quarter saw operational growth in key brands (Eliquis +22% operationally) while COVID products declined.
Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.
Pfizer (NYSE: PFE) and Astellas announced final Phase 3 EMBARK results showing that XTANDI plus leuprolide reduced the risk of death by 40.3% (HR 0.597; 95% CI 0.444-0.804; p=0.0006) versus leuprolide alone in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
The 8-year overall survival was 78.9% with XTANDI plus leuprolide vs 69.5% with leuprolide. Median follow-up was ~94 months. XTANDI monotherapy showed a numerical but not statistically significant OS improvement (HR 0.83; p=0.1867). Safety was consistent with prior analyses; common adverse events included hot flashes, fatigue and gynecomastia.
Pfizer (NYSE: PFE) reported updated Phase 2 PHAROS results for BRAFTOVI + MEKTOVI in BRAF V600E-mutant metastatic non-small cell lung cancer. In treatment-naïve patients median overall survival was 47.6 months (95% CI 31.3, NE) after a median follow-up of 52.3 months; previously treated patients had median OS 22.7 months after 48.2 months follow-up. Four-year OS rates were 49% (treatment-naïve) and 31% (previously treated). The ORR was 75% (treatment-naïve) and 46% (previously treated). Safety was consistent with prior data; most common TRAEs ≥30% included nausea, diarrhea, fatigue and vomiting. Data presented at ESMO 2025 and published in Journal of Clinical Oncology.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
